Reading the tape
NASDAQ: IDXX
IDEXX Laboratories, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$44.84B
52w High
$769.98
52w Low
$465.00
P/E
42.57
Volume
701.72K
Outstanding Shares
79.62M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 18.53%Revenue (TTM): 10.42%FCF (TTM): 31.99%P/FCF: 13th pct
What changed
The stock rose 18.53% over the last year. Revenue grew 10.42% over the trailing twelve months. Operating margin moved from 28.95% to 31.6%. Free cash flow grew 31.99% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 13th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 31.6%. Revenue grew 10.42% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
CEOJonathan J. Mazelsky
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees11,000
IPO dateJun 21, 1991
Valuation
Forward P/E—
EV/EBITDA37.50
Enterprise value$55.08B
Stock splits
Jun 16, 2015↑ Forward
Every 1 shares became 2
Nov 27, 2007↑ Forward
Every 1 shares became 2
Jun 6, 1995↑ Forward
Every 1 shares became 2
Oct 4, 1993↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth14.28%
Gross margin61.8%▲1.25%vs FY2024
Operating margin31.6%▲9.16%vs FY2024
ROE65.99%▲18.58%vs FY2024
Analyst consensus
RatingBuy
Target price$747.50▲32.74%
13
Buy
8
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $3.42 · Revenue est $1.12B
View